

# Karen Onel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2988092/publications.pdf>

Version: 2024-02-01

76  
papers

2,657  
citations

185998

28  
h-index

197535

49  
g-index

78  
all docs

78  
docs citations

78  
times ranked

2300  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1001-1010.	1.5	172
2	Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. <i>Arthritis Care and Research</i> , 2018, 70, 1228-1237.	1.5	128
3	Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 745-752.	1.5	126
4	Emergent high fatality lung disease in systemic juvenile arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1722-1731.	0.5	122
5	Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. <i>Arthritis and Rheumatism</i> , 2009, 60, 2772-2781.	6.7	121
6	Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. <i>Pediatric Nephrology</i> , 2008, 23, 403-412.	0.9	120
7	Long-Term Safety and Efficacy of Riloncept in Patients With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2486-2496.	6.7	109
8	Initial Validation of a Novel Protein Biomarker Panel for Active Pediatric Lupus Nephritis. <i>Pediatric Research</i> , 2009, 65, 530-536.	1.1	108
9	Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for New-Onset Polyarticular Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1063-1072.	1.5	101
10	Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. <i>Journal of Pediatrics</i> , 2004, 145, 856-857.	0.9	91
11	Levels of soluble fas/APO-1 /CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 1735-1737.	6.7	85
12	Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. <i>Pediatric Rheumatology</i> , 2013, 11, 29.	0.9	69
13	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 553-569.	2.9	68
14	Health-related Quality of Life and Its Relationship to Patient Disease Course in Childhood-onset Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 1536-1545.	1.0	61
15	Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults. <i>Arthritis Care and Research</i> , 2016, 68, 1003-1011.	1.5	54
16	Expression and function of the murine CD95/FasR/APO-1 receptor in relation to B cell ontogeny. <i>European Journal of Immunology</i> , 1995, 25, 2940-2947.	1.6	52
17	Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. <i>Journal of Pediatrics</i> , 2017, 184, 38-44.e1.	0.9	48
18	Multicenter validation of a new quality of life measure in pediatric lupus. <i>Arthritis and Rheumatism</i> , 2007, 57, 1165-1173.	6.7	46

#	ARTICLE	IF	CITATIONS
19	Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. <i>Journal of Pediatrics</i> , 2002, 140, 125-127.	0.9	45
20	Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. <i>Pediatric Rheumatology</i> , 2017, 15, 23.	0.9	41
21	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. <i>Arthritis and Rheumatology</i> , 2019, 71, 451-459.	2.9	36
22	Pediatric Rheumatology Collaborative Study Group " over four decades of pivotal clinical drug research in pediatric rheumatology. <i>Pediatric Rheumatology</i> , 2018, 16, 45.	0.9	35
23	Inactive disease and remission in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012, 64, 683-693.	1.5	34
24	Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. <i>Journal of Rheumatology</i> , 2017, 44, 352-360.	1.0	31
25	Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. <i>Pediatric Nephrology</i> , 2019, 34, 117-128.	0.9	31
26	Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010, 62, 950-959.	1.5	30
27	Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica. <i>Journal of Child Neurology</i> , 2011, 26, 244-247.	0.7	30
28	Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1213-1223.	1.5	28
29	Adding Canakinumab to the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Systemic Juvenile Idiopathic Arthritis: Comment on the Article by DeWitt et al. <i>Arthritis Care and Research</i> , 2014, 66, 1430-1431.	1.5	28
30	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1945-1951.	2.9	28
31	Title is missing!. <i>Journal of Pediatric Orthopaedics</i> , 2003, 23, 114-118.	0.6	27
32	Identifying Targets for Improving Mental Healthcare of Adolescents with Systemic Lupus Erythematosus: Perspectives from Pediatric Rheumatology Clinicians in the United States and Canada. <i>Journal of Rheumatology</i> , 2016, 43, 1136-1145.	1.0	27
33	Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016, 68, 195-202.	1.5	27
34	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 521-537.	1.5	27
35	Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 191-197.	0.8	26
36	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1508-1518.	2.9	26

#	ARTICLE	IF	CITATIONS
37	Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry. <i>Pediatric Rheumatology</i> , 2014, 12, 29.	0.9	25
38	Toward the development of criteria for global flares in juvenile systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010, 62, 811-820.	1.5	24
39	Gaps in Mental Health Care for Youth With Rheumatologic Conditions: A Mixed Methods Study of Perspectives From Behavioral Health Providers. <i>Arthritis Care and Research</i> , 2019, 71, 591-601.	1.5	24
40	Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 401-406.	0.5	23
41	Physical function assessment tools in pediatric rheumatology. <i>Pediatric Rheumatology</i> , 2008, 6, 9.	0.9	20
42	A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America. <i>Pediatric Rheumatology</i> , 2014, 12, 24.	0.9	20
43	Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. <i>Arthritis Care and Research</i> , 2010, 62, 1024-1028.	1.5	19
44	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. <i>Arthritis and Rheumatology</i> , 2021, 73, 1898-1909.	2.9	19
45	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 579-590.	1.5	15
46	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. <i>Arthritis Care and Research</i> , 2022, 74, 505-520.	1.5	15
47	Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010, 62, 335-344.	1.5	14
48	Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association With Pediatric Primary Sjogren Syndrome: 2 Cases and Review. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 413-416.	0.3	14
49	International Consensus for the Dosing of Corticosteroids in Childhood-onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 263-273.	2.9	14
50	Advances in the medical treatment of juvenile rheumatoid arthritis. <i>Current Opinion in Pediatrics</i> , 2000, 12, 72-75.	1.0	13
51	Quality of life in children with systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2005, 7, 447-452.	2.1	13
52	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1117-1126.	1.0	13
53	Chronic recurrent multifocal osteomyelitis: diagnosis and treatment. <i>Current Opinion in Pediatrics</i> , 2021, 33, 90-96.	1.0	13
54	Engaging patients and parents to improve mental health intervention for youth with rheumatological disease. <i>Pediatric Rheumatology</i> , 2021, 19, 19.	0.9	12

#	ARTICLE	IF	CITATIONS
55	Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey. <i>Pediatric Rheumatology</i> , 2019, 17, 48.	0.9	11
56	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. <i>Arthritis and Rheumatology</i> , 2022, 74, 570-585.	2.9	11
57	SYSTEMIC LUPUS ERYTHEMATOSUS IN A PEDIATRIC PATIENT WITH CONGENITAL ACQUIRED IMMUNODEFICIENCY SYNDROME. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 450-452.	1.1	10
58	Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives. <i>Annals of Medicine</i> , 2022, 54, 1839-1850.	1.5	10
59	Glitches in the utilization of telehealth in pediatric rheumatology patients during the COVID-19 pandemic. <i>Pediatric Rheumatology</i> , 2020, 18, 78.	0.9	9
60	Novel Method to Collect Medication Adverse Events in Juvenile Arthritis: Results From the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project. <i>Arthritis Care and Research</i> , 2015, 67, 529-537.	1.5	8
61	Juvenile Idiopathic Arthritis Treatment Updates. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 545-563.	0.8	8
62	Tumor necrosis factor inhibitors and cancer in juvenile idiopathic arthritis: Disentangling the web. <i>Arthritis and Rheumatism</i> , 2012, 64, 966-969.	6.7	7
63	Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. <i>Pediatric Rheumatology</i> , 2021, 19, 122.	0.9	7
64	Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 957-961.	1.6	7
65	Contraception for adolescents with lupus. <i>Pediatric Rheumatology</i> , 2010, 8, 10.	0.9	6
66	Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. <i>Pediatric Rheumatology</i> , 2022, 20, 18.	0.9	6
67	The Clinical Spectrum of Juvenile Idiopathic Arthritis in a Large Urban Population. <i>Current Rheumatology Reports</i> , 2012, 14, 116-120.	2.1	4
68	Multicenter Study of Utility and Acceptability of Depression and Anxiety Screening in Adolescents and Young Adults With Childhood-Onset Systemic Lupus. <i>Arthritis Care and Research</i> , 2023, 75, 724-733.	1.5	3
69	Update on Juvenile Spondyloarthritis. <i>Pediatrics in Review</i> , 2021, 42, 581-589.	0.2	1
70	Response to "Care needs to be taken when reviewing malignancy data reported from observational studies" by Mariette, et al. <i>Arthritis Care and Research</i> , 2010, 63, n/a-n/a.	1.5	0
71	FRI0019...URINARY TRANSCRIPTS AS BIOMARKERS OF LUPUS NEPHRITIS. , 2019, , .		0
72	Engaging patients and parents to improve mental health for youth with systemic lupus erythematosus. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	Challenges to Practicing Pediatric Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, 67-78.	0.8	0
74	Lyme disease presenting as persistent severe photophobia. Journal of AAPOS, 2021, 25, 52-54.	0.2	0
75	1501â€¦Genetics of age at systemic lupus erythematosus diagnosis. , 2021, , .		0
76	503â€¦Developing a standardized steroid dosing regimen in pediatric proliferative lupus nephritis. , 2021, , .		0